Cours Mateon Therapeutics, Inc. Other OTC
Actions
MATN
US57667K1097
Recherche biotechnologique et médicale
CA 2022 | - | CA 2023 | 0,07 0,06 | Capitalisation | 15,27 M 13,99 M |
---|---|---|---|---|---|
Résultat net 2022 | 5 M 4,58 M | Résultat net 2023 | -7 M -6,41 M | VE / CA 2022 | - |
Dette nette 2022 | 11,02 M 10,09 M | Dette nette 2023 | 12,4 M 11,36 M | VE / CA 2023 | 395 316 686 x |
PER 2022 |
4,5
x | PER 2023 |
-1,91
x | Employés | - |
Rendement 2022 * |
-
| Rendement 2023 |
-
| Flottant | 45,03% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22/04/19 |
Director of Finance/CFO | 57 | 01/07/19 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 06/01/20 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Steven W. King
BRD | Director/Board Member | 59 | 11/05/20 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 11/05/20 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22/04/19 |
Varia. 1 janv. | Capi. | |
---|---|---|
-1,17% | 104 Md | |
+2,87% | 97,47 Md | |
+2,13% | 22,25 Md | |
-14,77% | 21,68 Md | |
-8,79% | 18,2 Md | |
-39,98% | 17,02 Md | |
-13,21% | 16,36 Md | |
+8,55% | 14,39 Md | |
+35,75% | 12,37 Md |